TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05894382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Helix Design Defocus Lens Spectacle (RACE)
Description: Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Double Helix Design Defocus Lens Spectacle (RACE)
Description: Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: single-vision spetacle lens
Description: single-vision spetacle lens wearing more than 10h/day.
Study: NCT05020730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM-001
Description: PTM-001 (400 mg) every day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo every day for 12 weeks
Study: NCT06611475

Intervention type: OTHER
Intervention: MMSE ≤26
Description: A dataset comprising participants with MMSE scores of ≤26 and 30 will be used to evaluate the classification performance of various machine learning techniques.

Intervention type: OTHER
Intervention: MMSE ≤26
Description: A dataset comprising participants with MMSE scores of ≤26 and 30 will be used to evaluate the classification performance of various machine learning techniques.
Study: NCT06068894

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Humanized galacto-oligosaccharides (hGOS)
Description: 10-15 g/day of hGOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS)
Description: 10-15 g/day of GOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: 10-15 g/day powdered corn syrup comprised of fructose, glucose, and an inert cellulose material that matches the consistency, color sweetness, and taste of the prebiotics, that can be added to any non-alcoholic beverage.
Study: NCT05838222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solution Focused Intervention
Description: A short term, goal focused, therapeutic approach which helps patients address problems contributing to health and mental health challenges

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The patient receives standardized care from primary care team without the SFBT intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The patient receives standardized care from primary care team without the SFBT intervention
Study: NCT04557722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0-30° Biplanar Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy
Description: after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-30 degree technique of C-Arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: New 0-90° Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy
Description: after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-90 degree technique of C-Arm.
Study: NCT05595798

Intervention type: DIAGNOSTIC_TEST
Intervention: Airmod breathing sound monitoring
Description: Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Airmod breathing sound monitoring
Description: Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.
Study: NCT06408454

Intervention type: DIAGNOSTIC_TEST
Intervention: Gingival crevicular fluid collection
Description: Samples were taken from two mandibular molar teeth. Before sampling, the sites were isolated with cotton rolls and then carefully dried with an air syringe to avoid saliva contamination. GCF was collected using sterile periodontal strips by gently inserting them into the gingival sulcus or pocket until slight resistance was noticed. After 30 s, the strips were collected into sterile tubes and immediately transported to the laboratory for storage (-40 °C) and posterior analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gingival crevicular fluid collection
Description: Samples were taken from two mandibular molar teeth. Before sampling, the sites were isolated with cotton rolls and then carefully dried with an air syringe to avoid saliva contamination. GCF was collected using sterile periodontal strips by gently inserting them into the gingival sulcus or pocket until slight resistance was noticed. After 30 s, the strips were collected into sterile tubes and immediately transported to the laboratory for storage (-40 °C) and posterior analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: periodontal test
Description: A periodontist conducted the periodontal evaluation, which included a comprehensive assessment of clinical periodontal status, a full mouth manual periodontal charting, measurement of probing depth, clinical attachment level, bleeding on probing, and evaluation of mobility using a periotest device. Additionally, information regarding the patient's smoking status, frequency of smoking, and oral hygiene habits was obtained.

Intervention type: DIAGNOSTIC_TEST
Intervention: periodontal test
Description: A periodontist conducted the periodontal evaluation, which included a comprehensive assessment of clinical periodontal status, a full mouth manual periodontal charting, measurement of probing depth, clinical attachment level, bleeding on probing, and evaluation of mobility using a periotest device. Additionally, information regarding the patient's smoking status, frequency of smoking, and oral hygiene habits was obtained.
Study: NCT04282733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Rounds
Description: Throughout the 8-week study period, a different mindfulness practice will be introduced weekly in 3 separate 15-minute live sessions. Posters describing the particular practice of the week will be placed around the Unit as visual reminders to encourage actual practice.
Study: NCT05199545

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement
Description: Dietary supplement under study is based on Rhodiola rosea L. and Crocus sativus L. extracts

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of the dietary supplement
Study: NCT04929522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: technique for local anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: technique for local anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: technique for local anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: technique for local anesthesia
Study: NCT06016413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adelbelimumab
Description: All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
Study: NCT05414019

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mini-screw
Description: 7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Utility arch
Description: 7 patients will receive an intrusive force delivered by intrusive utility arch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitinol reverse curve wire
Description: 7 patients will receive an intrusive force delivered by Nitinol reverse curve wire
Study: NCT04832984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health
Description: Participants will be issued a fitness tracker, Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (biweekly bite-sized content over 24 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
Study: NCT06678191

Intervention type: DRUG
Intervention: BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg
Description: In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist.
Study: NCT06675695

Intervention type: DRUG
Intervention: New use of osimertinib
Description: New use of osimertinib described in electronic health records is used as the exposure.

Intervention type: DRUG
Intervention: New use of erlotinib or gefitinib
Description: New use of standard of care described in electronic health records (erlotinib or gefitinib) dispensing claim is used as the reference.
Study: NCT06319339

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vumerity
Description: diroximal fumarate 462 mg (2 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vumerity
Description: diroximal fumarate 462 mg (2 capsules)
Study: NCT05264038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC514 (Mid dose)
Description: Mid dose level of OC514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC514 (High dose)
Description: High dose level of OC514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match
Study: NCT06319339

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vumerity
Description: diroximal fumarate 462 mg (2 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vumerity
Description: diroximal fumarate 462 mg (2 capsules)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose 462 mg (2 capsules)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Microcrystalline cellulose 462 mg (2 capsules)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose 462 mg (2 capsules)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Microcrystalline cellulose 462 mg (2 capsules)
Study: NCT05443009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: A buccal infiltration injection followed by palatal injections and interpapillary injections of 2% lidocaine with 1:100,000 epinephrine will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
Study: NCT05812924

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Description: 0.1-0.2 mL injections of platelet-rich plasma (PRP) will be injected to the vulvovaginal area. The injections will be placed every 5mm and at an angle of 60° into the mucosa and lamina propria of the posterior wall of the vagina.
Study: NCT06694857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA filler
Description: patient will receive FDA approved dosages of filler to the lower face region to treat facial contour or asymmetry, as per FDA approved indications. Patients are limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (132 lbs) body mass per year. Prior to injection patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging.
Study: NCT06697483

Intervention type: DRUG
Group type: OTHER
Intervention: Daratumumab
Description: Patients who are R2-ISS 3 or 4 OR MRD (Minimal Residual Disease) positivity will receive daratumumab plus lenalidomide maintenance.

Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: Patients are R2-ISS 1,2 and MRD (Minimal Residual Disease) negative after autologous stem cell transplantation.~Patients will receive the single drug lenalidomide maintenance.

Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: Patients are R2-ISS 1,2 and MRD (Minimal Residual Disease) negative after autologous stem cell transplantation.~Patients will receive the single drug lenalidomide maintenance.
Study: NCT06701292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVS-PVI targeted ablation
Description: Omnipolar technology will be used to analyze all PVs and delineate the PVMS. Once identified, PVMS will be marked and described in a clockface fashion using a lateral view of the vein.Ablation will target the PVMS using the same power and force parameters as described for the WACA procedure. Effective ablation lesions and distance between ablation spots will be represented in the same manner too. Lesions should cover at least 5 mm outside the PVMS delineation on both PVMS borders of each myocardial sleeve. PVI will be demonstrated with the same technique described in the WACA procedure.~The PVI will be verified for each vein 10 minutes after the initial achievement of PVI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wide area circumferential ablation (WACA)
Description: After generating the 3D electroanatomical map of the heart to understand where treatment needs to be applied,using a tool called radiofrequency (RF) ablation, small burns will be made around the veins to block abnormal electrical signals. Each burn is applied with up to 50 watts of power and lasts up to 10 seconds.The ablation tool will press down with a force of around 10-20 grams.The mapping system (NAVX software) shows the burns on the 3D map
Study: NCT06700811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The ketogenic diet formula will be supplied by KetoVie®. Ketogenic diet ratio will aim to achieve ketosis, with a minimum level of beta-hydroxybutyrate of 0.3mmol/L. Ratios of ketogenic diet generally range from 1:1 to 4:1 (goal 4:1, minimum 1:1 if required for tolerance or high BHB) and will not exceed this ratio. Higher ratios are often required to obtain ketosis of ideally 2-5mmol/L in infants.
Study: NCT06702345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: encapsulated 10^4 CFU toxigenic. C. difficile spores
Description: 12 consecutive days of once a day a capsule with 10\^4 CFU toxigenic C. difficile spores.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: encapsulated 10^4 CFU toxigenic. C. difficile spores
Description: 12 consecutive days of once a day a capsule with 10\^4 CFU toxigenic C. difficile spores.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: encapsulated 10^4 CFU toxigenic. C. difficile spores
Description: 12 consecutive days of once a day a capsule with 10\^4 CFU toxigenic C. difficile spores.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: oral vancomycin pretreatment, 4 times a day 250mg, given the five days before toxigenic C. difficile exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: oral clindamycin pretreatment, 3 times a day 600mg, given the five days before toxigenic C. difficile exposure
Study: NCT06701032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular rehabilitation program
Description: The cardiovascular rehabilitation program consists of a 12 weeks supervised exercises therapy (either in person or in tele-care)
Study: NCT06702085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Management
Description: patients administered supervised changes in their lifestyle (walking exercise for 40 minutes applied on treadmill for three time per week and low caloric diet) for twelve weeks
Study: NCT06700447

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced inoculation message
Description: Participants enrolled in the enhanced inoculation message arm will receive a similar inoculation message that is enhanced with insights from behavioural economics. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. Following this message delivery, all participants will view/watch claims about the HIV vaccine some of which will be false or misleading. The vaccine misinformation claims will be presented using language (and in some cases, visual imagery) consistent with how misinformation exposure will occur in the information ecology (i.e., through social networks and in traditional and social media in real-world settings).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard inoculation message
Description: Participants enrolled in the standard inoculation message arm will receive a message that warns them about impending HIV vaccine misinformation and explains why that claim is false or misleading. Following this message delivery, all participants will view/watch claims about the HIV vaccine some of which will be false or misleading. The vaccine misinformation claims will be presented using language (and in some cases, visual imagery) consistent with how misinformation exposure will occur in the information ecology (i.e., through social networks and in traditional and social media in real-world settings).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition information
Description: Participants enrolled in the control group will receive unrelated information on nutrition topics of the same length as the inoculation messages. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.
Study: NCT06632509

Intervention type: DEVICE
Intervention: BD SiteRite(TM) 9
Description: Ultrasound-guided vascular access device placement procedure using the BD SiteRite(TM) 9.
Study: NCT06700746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Prolotherapy is an injection of a relatively small volume of an irritant or sclerosing solution at sites of painful ligament and/or tendon insertions, and in adjacent joint space over the course of several treatment sessions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT)
Description: Extracorporeal shock wave therapy (ESWT), a kind of physical modalities, generating acoustic pulses, that are high positive pressure amplitudes, subsequently transferring concentrated energy to small focal distant areas of 2-8 mm in diameter
Study: NCT06700655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cornea limbal stem cell transplantation group
Description: The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal transplantation
Description: The patient awaited allogeneic corneal donation and underwent corneal transplantation surgery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cornea limbal stem cell transplantation combined corneal stromal stem cell group
Description: The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells and corneal stromal stem cells.
Study: NCT06702163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (active)
Description: Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (sham)
Description: In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
Study: NCT05820542

Intervention type: OTHER
Intervention: miller laryngoscope
Description: The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
Study: NCT06701201

Intervention type: DRUG
Intervention: SynKIR-110
Description: Autologous T cells Transduced with Mesothelin KIR-CAR

Intervention type: DRUG
Intervention: SynKIR-310
Description: Autologous T Cells transduced with CD19 KIR-CAR
Study: NCT06701708

Intervention type: OTHER
Intervention: Participants are not assigned to interventions based on a protocol.
Description: Participants are not assigned to interventions based on a protocol.